[go: up one dir, main page]

PL2415763T3 - Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry - Google Patents

Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry

Info

Publication number
PL2415763T3
PL2415763T3 PL10758728T PL10758728T PL2415763T3 PL 2415763 T3 PL2415763 T3 PL 2415763T3 PL 10758728 T PL10758728 T PL 10758728T PL 10758728 T PL10758728 T PL 10758728T PL 2415763 T3 PL2415763 T3 PL 2415763T3
Authority
PL
Poland
Prior art keywords
treating
pharmaceutical composition
preventing glaucoma
glaucoma
preventing
Prior art date
Application number
PL10758728T
Other languages
English (en)
Inventor
Masahiko Hagihara
Kenji Yoneda
Eiji Okanari
Manabu Shigetomi
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries filed Critical Ube Industries
Publication of PL2415763T3 publication Critical patent/PL2415763T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/83—Thioacids; Thioesters; Thioamides; Thioimides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10758728T 2009-03-30 2010-03-30 Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry PL2415763T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009082725 2009-03-30
EP10758728.9A EP2415763B1 (en) 2009-03-30 2010-03-30 Pharmaceutical composition for treating or preventing glaucoma
PCT/JP2010/055719 WO2010113957A1 (ja) 2009-03-30 2010-03-30 緑内障の治療又は予防のための医薬組成物

Publications (1)

Publication Number Publication Date
PL2415763T3 true PL2415763T3 (pl) 2016-05-31

Family

ID=42828246

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10758728T PL2415763T3 (pl) 2009-03-30 2010-03-30 Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry

Country Status (18)

Country Link
US (1) US8685986B2 (pl)
EP (1) EP2415763B1 (pl)
JP (2) JP5300033B2 (pl)
KR (1) KR101681347B1 (pl)
CN (1) CN102448940B (pl)
AU (1) AU2010231630B2 (pl)
CA (1) CA2757291C (pl)
CY (1) CY1117193T1 (pl)
DK (1) DK2415763T3 (pl)
ES (1) ES2564010T3 (pl)
HK (1) HK1170490A1 (pl)
HR (1) HRP20160104T1 (pl)
HU (1) HUE026742T2 (pl)
PL (1) PL2415763T3 (pl)
PT (1) PT2415763E (pl)
SI (1) SI2415763T1 (pl)
SM (1) SMT201600055B (pl)
WO (1) WO2010113957A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5136640B2 (ja) * 2008-03-12 2013-02-06 宇部興産株式会社 ピリジルアミノ酢酸化合物
CN102448940B (zh) 2009-03-30 2015-10-21 宇部兴产株式会社 用于青光眼的治疗或预防的医药组合物
AU2010293410A1 (en) * 2009-09-11 2012-05-03 Ube Industries, Ltd. Substituted carbonyl compounds
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
CN102666490A (zh) 2009-12-25 2012-09-12 宇部兴产株式会社 氨基吡啶化合物
CA2878370C (en) * 2012-07-13 2021-01-19 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
US9339496B2 (en) 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
KR20150135460A (ko) 2013-03-28 2015-12-02 우베 고산 가부시키가이샤 치환 비아릴 화합물
KR101858373B1 (ko) * 2014-01-10 2018-05-15 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물과 폴리옥시에틸렌 피마자유를 함유하는 의약 조성물
EP3093019B1 (en) * 2014-01-10 2021-05-26 Santen Pharmaceutical Co., Ltd Pharmaceutical composition containing pyridylamino acetic acid compound
UA117506C2 (uk) * 2014-01-10 2018-08-10 Сантен Фармас'Ютікал Ко., Лтд. Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти
JP6572890B2 (ja) * 2014-06-10 2019-09-11 宇部興産株式会社 ヘテロ芳香族スルホンアミド化合物の製造方法
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
CN106458904B (zh) * 2014-06-10 2021-12-03 宇部兴产株式会社 N-取代磺酰胺化合物及其制造方法
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
US20180185489A1 (en) * 2015-07-01 2018-07-05 Santen Pharmaceutical Co., Ltd. Depot preparation containing citric acid ester
EP3320904B1 (en) 2015-07-09 2023-07-05 Santen Pharmaceutical Co., Ltd. Preventative and/or therapeutic agent containing pyridyl aminoacetic acid compound for treating a disease involving a greatly elevated intraocular pressure
TWI842679B (zh) * 2017-09-29 2024-05-21 日商參天製藥股份有限公司 含有吡啶基胺乙酸化合物之醫藥
ES2972934T3 (es) 2017-12-21 2024-06-17 Santen Pharmaceutical Co Ltd Combinación de sepetaprost y ripasudil para su uso en la profilaxis o tratamiento del glaucoma o hipertensión ocular
WO2019124487A1 (ja) 2017-12-21 2019-06-27 参天製薬株式会社 オミデネパグの組合せ
EP3733179A4 (en) 2017-12-28 2021-09-15 Santen Pharmaceutical Co., Ltd. PHARMACEUTICAL PREPARATION CONTAINING A PYRIDYLAMINOACETIC ACID COMPOUND
KR20220089106A (ko) 2020-12-21 2022-06-28 이성규 도르졸라마이드 또는 폴리소르베이트80을 유효성분으로 포함하는 점안용 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
TR200002182T2 (tr) 1998-01-27 2000-12-21 Aventis Pharmaceuticals Products Inc. İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
NZ531153A (en) 2001-08-09 2005-10-28 Ono Pharmaceutical Co Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
WO2003037433A1 (en) 2001-10-26 2003-05-08 Allergan, Inc. Co-cycloalkyl 17-heteroaryl prostaglandin e2 analogs as ep2-receptor agonists
EA200400724A1 (ru) 2002-01-31 2004-12-30 Пфайзер Продактс Инк. Метаболиты (3-{[(4-трет-бутилбензил)-(пиридин-3-сульфонил)амино]метил}фенокси)уксусной кислоты
RU2306309C2 (ru) 2002-03-05 2007-09-20 Оно Фармасьютикал Ко., Лтд. Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний
US20070000939A1 (en) 2002-10-29 2007-01-04 Vasilios Vasiadis Device for handling and orientating pills or tablets in a precise manner
CN1859903A (zh) 2003-03-04 2006-11-08 辉瑞产品公司 Ep2选择性受体激动剂在药物治疗中的应用
GB0329620D0 (en) 2003-12-22 2004-01-28 Pharmagene Lab Ltd EP2 receptor agonists
WO2005072743A1 (ja) 2004-01-30 2005-08-11 Ono Pharmaceutical Co., Ltd. 気管支拡張剤
JP2007186424A (ja) 2004-11-26 2007-07-26 Ono Pharmaceut Co Ltd 気管支拡張剤
EP1714961B1 (en) 2004-02-12 2015-12-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
EP1593671A1 (en) 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
JP2008503490A (ja) 2004-06-17 2008-02-07 センジェント・セラピューティクス・インコーポレイテッド チロシンホスファターゼの三置換窒素調節物質
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
ES2346685T3 (es) 2005-01-14 2010-10-19 F. Hoffmann-La Roche Ag Deribados de tiazol-4-carboxamida como antagonistas de mglur5.
JP4874958B2 (ja) 2005-03-30 2012-02-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジン誘導体を含有する抗真菌剤
CA2616608A1 (en) 2005-08-03 2007-02-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
AU2006277786B2 (en) 2005-08-09 2012-09-06 Asterand Uk Acquisition Limited EP2 receptor agonists
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
MX2009001062A (es) 2006-07-28 2009-02-06 Pfizer Prod Inc Agonistas de ep2.
FI123744B (fi) * 2006-09-06 2013-10-15 Sandvik Mining & Constr Oy Menetelmä kallion poraamiseksi
JP5136640B2 (ja) 2008-03-12 2013-02-06 宇部興産株式会社 ピリジルアミノ酢酸化合物
CN102448940B (zh) 2009-03-30 2015-10-21 宇部兴产株式会社 用于青光眼的治疗或预防的医药组合物

Also Published As

Publication number Publication date
JPWO2010113957A1 (ja) 2012-10-11
JP5556924B2 (ja) 2014-07-23
CA2757291A1 (en) 2010-10-07
EP2415763A1 (en) 2012-02-08
KR101681347B1 (ko) 2016-11-30
SMT201600055B (it) 2016-04-29
US20120190852A1 (en) 2012-07-26
AU2010231630A1 (en) 2011-11-10
AU2010231630B2 (en) 2015-02-12
WO2010113957A1 (ja) 2010-10-07
PT2415763E (pt) 2016-03-30
HUE026742T2 (en) 2016-07-28
HK1170490A1 (zh) 2013-03-01
US8685986B2 (en) 2014-04-01
ES2564010T3 (es) 2016-03-17
EP2415763A4 (en) 2012-08-15
CN102448940A (zh) 2012-05-09
JP5300033B2 (ja) 2013-09-25
HRP20160104T1 (hr) 2016-03-25
CY1117193T1 (el) 2017-04-05
SI2415763T1 (sl) 2016-05-31
EP2415763B1 (en) 2016-01-27
JP2013151548A (ja) 2013-08-08
CN102448940B (zh) 2015-10-21
DK2415763T3 (en) 2016-03-07
KR20120003475A (ko) 2012-01-10
CA2757291C (en) 2017-05-23

Similar Documents

Publication Publication Date Title
HK1170490A1 (zh) 用於青光眼的治療或預防的醫藥組合物
HK1247821A1 (zh) 用於預防或治療眼科病症的方法和組合物
HK1231408A1 (zh) 藥物組合物
HK1169941A1 (zh) 治療外周血管疾病的組合物
EP2379077A4 (en) PHARMACEUTICAL COMPOSITION
HU0900072D0 (en) Transdermal pharmaceutical compositions
PL2429507T3 (pl) Kompozycja farmaceutyczna wolna od fosforanów do leczenia jaskry
SG10201408508YA (en) Combination composition useful for treating cardiovascular diseases
EP2465512A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING PAIN
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
ZA201204341B (en) Pharmaceutical composition for treating gutaneous burns
ZA201201894B (en) Pharmaceutical combination for treating tumor
HK1145399A1 (en) Pharmaceutical composition for treating hemorrhoids
PL2263454T3 (pl) Kompozycja uzdatniająca
EP2382992A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADIPOSITAS OR DIABETES
GB0919650D0 (en) Pharmaceutical composition
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych
EP2785343A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HYPERLIPIDEMIA
GB2486713B (en) Pharmaceutical composition for treating urinary system disorders
PT2566506T (pt) Composição de vacina para a prevenção ou tratamento de leishmanioses
HU0900010D0 (en) Improved pharmaceutical composition
GB0906255D0 (en) Sleep-induced ophthalmic composition